Urinary microbiome-based metagenomic signature for the noninvasive diagnosis of hepatocellular carcinoma

Br J Cancer. 2024 Apr;130(6):970-975. doi: 10.1038/s41416-024-02582-1. Epub 2024 Jan 26.

Abstract

Background: Gut microbial dysbiosis is implicated in chronic liver disease and hepatocellular carcinoma (HCC), but the role of microbiomes from various body sites remains unexplored. We assessed disease-specific alterations in the urinary microbiome in HCC patients, investigating their potential as diagnostic biomarkers.

Methods: We performed cross-sectional analyses of urine samples from 471 HCC patients and 397 healthy controls and validated the results in an independent cohort of 164 HCC patients and 164 healthy controls. Urinary microbiomes were analyzed by 16S rRNA gene sequencing. A microbial marker-based model distinguishing HCC from controls was built based on logistic regression, and its performance was tested.

Results: Microbial diversity was significantly reduced in the HCC patients compared with the controls. There were significant differences in the abundances of various bacteria correlated with HCC, thus defining a urinary microbiome-derived signature of HCC. We developed nine HCC-associated genera-based models with robust diagnostic accuracy (area under the curve [AUC], 0.89; balanced accuracy, 81.2%). In the validation, this model detected HCC with an AUC of 0.94 and an accuracy of 88.4%.

Conclusions: The urinary microbiome might be a potential biomarker for the detection of HCC. Further clinical testing and validation of these results are needed in prospective studies.

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Cross-Sectional Studies
  • Humans
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / pathology
  • Microbiota* / genetics
  • Prospective Studies
  • RNA, Ribosomal, 16S / genetics

Substances

  • RNA, Ribosomal, 16S